Table 1 Patient demographics and clinical characteristics.
From: The diagnostic value of serum Ephrin-A1 in patients with colorectal cancer
Variable | Test cohort | Validation cohort | ||
|---|---|---|---|---|
CRC patients (n = 121) | Normal control (n = 108) | CRC patients (n = 119) | Normal control (n = 118) | |
Age (years) | ||||
Mean ± SD | 64 ± 12 | 50 ± 15 | 65 ± 11 | 51 ± 11 |
Range | 26–85 | 25–83 | 33–88 | 36–82 |
Gender | ||||
Male | 69 (57.02%) | 70 (64.81%) | 72 (60.50%) | 77 (65.25%) |
Female | 52 (42.98%) | 38 (35.19%) | 47 (39.50%) | 41 (34.75%) |
Location | ||||
Colon | 83 (68.60%) | 65 (54.62%) | ||
Rectum | 38 (31.40%) | 54 (45.38%) | ||
Tumor size | ||||
<=5 cm | 64 (52.89%) | 55 (46.22%) | ||
> 5 cm | 51 (42.15%) | 28 (23.53%) | ||
Unknown | 6 (4.96%) | 36 (30.25%) | ||
Grade | ||||
Low | 0 (0%) | 11 (9.24%) | ||
Moderate | 98 (80.99%) | 59 (49.58%) | ||
High | 2 (1.65%) | 3 (2.52%) | ||
Unknown | 21 (17.36%) | 46 (38.66%) | ||
Invasion depth | ||||
Tis | 0 (0%) | 1 (0.84%) | ||
T1 | 2 (1.65%) | 5 (4.2%) | ||
T3 | 12 (9.92%) | 10 (8.40%) | ||
T3 | 10 (8.26%) | 28 (23.53%) | ||
T4 | 93 (76.86%) | 62 (52.10%) | ||
Unknown | 4 (3.31%) | 13 (10.92%) | ||
Lymphatic metastasis | ||||
N0 | 61 (50.41%) | 49 (41.18%) | ||
N1 | 36 (29.75%) | 31 (26.05%) | ||
N2 | 16 (13.22%) | 15 (12.61%) | ||
N3 | 2 (1.65%) | 1 (0.845%) | ||
Unknown | 6 (4.96%) | 21 (17.65%) | ||
Distant metastasis | ||||
M0 | 102 (84.30%) | 77 (64.71%) | ||
M1 | 14 (11.57%) | 20 (16.81%) | ||
Unknown | 5 (4.13%) | 22 (18.49%) | ||
TNM stage | ||||
I-IIA | 20 (16.53%) | 32 (26.89%) | ||
IIB-IV | 97 (80.17%) | 72 (60.50%) | ||
Unknown | 4 (3.31%) | 15 (12.61%) | ||
